RENAL CELL CARCINOMA -  BEVACIZUMAB, SORAFENIB, SUNITINIB AND TEMSIROLIMUS

NICE Appraisal

TA178  Bevacizumab, sorafenib, sunitinib and temsirolimus for advanced and/or metastatic renal cell carcinoma

 

DSU Reports

2009
Response from the DSU to comments on the extra work consultation
(February 2009)

Extra work done by the DSU on the revised analyses submitted by Bayer (January 2009)

DSU addendum to the review of Roche's request for parameter changes (January 2009)

2008
Bevacizumab, sorafenib, sunitinib and temsirolimus for renal cell carcinoma
(September 2008)

Additional analysis by assessment group and DSU (September 2008)

 

To receive notification when new reports or documents are uploaded to this website, please join our mailing list by entering your details on the right of this page or follow us on Twitter @NICE_DSU